{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:39:02Z","timestamp":1792093142203,"version":"4.4.0"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2023,2]]},"abstract":"During development of a drug, the requirement of evaluating the proarrhythmic risk and delayed repolarization needs to be fulfilled. Would it be possible to create an alternative to a thorough QT (TQT) study or is there a need to perform a dedicated TQT study? How is an alternative approach generated, what information is available, and which instructions are considered missing today to generate such an approach? This tutorial describes the considerations and path followed to create an early and feasible alternative to a TQT study using experience\u2010based insights from a successful application to the US Food and Drug Administration for GLPG1972, an ADAMTS\u20105 inhibitor, and discusses the approach used in light of the current guidelines and literature.<\/jats:p>","DOI":"10.1002\/cpt.2596","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T06:24:51Z","timestamp":1648707891000},"page":"310-320","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example"],"prefix":"10.1111","volume":"113","author":[{"given":"Claudia","family":"Meyer","sequence":"first","affiliation":[{"name":"Galapagos B.V. Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Dierick","sequence":"additional","affiliation":[{"name":"Galapagos NV Mechelen Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Gauderat","sequence":"additional","affiliation":[{"name":"Translational Medicine Division Servier Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Langenhorst","sequence":"additional","affiliation":[{"name":"Pharmetheus A.B. Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Sarr","sequence":"additional","affiliation":[{"name":"Pharmetheus A.B. Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Leroux","sequence":"additional","affiliation":[{"name":"Translational Medicine Division Servier Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marylore","family":"Chenel","sequence":"additional","affiliation":[{"name":"Pharmetheus A.B. Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Fouliard","sequence":"additional","affiliation":[{"name":"Translational Medicine Division Servier Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Passier","sequence":"additional","affiliation":[{"name":"Galapagos B.V. Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"ICH.E14 Guideline. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs (2005). Accessed July 19 2021."},{"key":"e_1_2_11_3_1","unstructured":"ICH S7B Guideline.The non\u2010clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (2005)."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.60"},{"key":"e_1_2_11_5_1","unstructured":"ICH E14 Guideline.The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs. Questions & Answers (R3) (2015). Accessed July 19 2021."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9558-5"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9565-6"},{"key":"e_1_2_11_8_1","unstructured":"ICH. E14\/S7B Implementation Working Group.Clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential. Questions & Answers (Draft Version\u2013Step 2b) (2020). Accessed July 19 2021."},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.779"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.804"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aem214"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2137"},{"key":"e_1_2_11_13_1","unstructured":"ICH E14\/S7B Webinar.New approaches for an integrated nonclinical\u2013clincal QT\/proarrhythmic risk assessment."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2029"},{"key":"e_1_2_11_15_1","unstructured":"EMA.Guideline on strategies to identify and mitigate risks for first\u2010in\u2010human and early clinical trials with investigational medicinal products (2018). Accessed July 19 2021."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1374"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011419851"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2015.01.006"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04376.x"}],"container-title":["Clinical Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2596","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.2596","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:31:25Z","timestamp":1699363885000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/cpt.2596"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2596","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"2021-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}